Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Tg Therapeutics (TGTX) Gross Margin: 2016-2025

Historic Gross Margin for Tg Therapeutics (TGTX) over the last 10 years, with Sep 2025 value amounting to 82.63%.

  • Tg Therapeutics' Gross Margin fell 624.00% to 82.63% in Q3 2025 from the same period last year, while for Sep 2025 it was 85.34%, marking a year-over-year decrease of 297.00%. This contributed to the annual value of 88.30% for FY2024, which is 565.00% down from last year.
  • As of Q3 2025, Tg Therapeutics' Gross Margin stood at 82.63%, which was down 4.57% from 86.58% recorded in Q2 2025.
  • Tg Therapeutics' 5-year Gross Margin high stood at 100.00% for Q2 2021, and its period low was 82.14% during Q4 2023.
  • Its 3-year average for Gross Margin is 88.02%, with a median of 88.11% in 2023.
  • In the last 5 years, Tg Therapeutics' Gross Margin tumbled by 1,753bps in 2021 and then spiked by 1,753bps in 2022.
  • Quarterly analysis of 5 years shows Tg Therapeutics' Gross Margin stood at 100.00% in 2021, then plummeted by 375bps to 96.25% in 2022, then tumbled by 1,411bps to 82.14% in 2023, then soared by 363bps to 85.77% in 2024, then tumbled by 624bps to 82.63% in 2025.
  • Its last three reported values are 82.63% in Q3 2025, 86.58% for Q2 2025, and 87.14% during Q1 2025.